摘要
目的分析氟桂利嗪联合尼莫地平治疗偏头痛患者的临床效果。方法100例偏头痛患者,依照就诊顺序分为对照组与观察组,每组50例。对照组患者使用尼莫地平治疗,观察组患者在对照组基础上使用氟桂利嗪治疗。比较两组患者治疗效果,治疗前后疼痛评分、持续时间、发作次数及不良反应发生情况。结果观察组治疗总有效率为96.00%,明显高于对照组的76.00%,差异有统计学意义(P<0.05)。治疗前,两组患者疼痛评分、持续时间、发作次数比较,差异无统计学意义(P>0.05)。治疗后,两组患者疼痛评分均低于治疗前,持续时间均短于治疗前,发作次数均少于治疗前,差异有统计学意义(P<0.05),且观察组患者疼痛评分低于对照组,持续时间短于对照组,发作次数少于对照组,差异有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论氟桂利嗪联合尼莫地平治疗偏头痛患者,可以明显提高临床疗效,缩短持续时间,减少发作次数,且安全性高,值得进一步在临床中推广。
Objective To analyze the clinical effect of flunarizine combined with nimodipine in the treatment of migraine. Methods A total of 100 migraine patients were divided by visiting order into control group and observation group, with 50 cases in each group. The control group was treated with nimodipine, and the observation group was treated with flunarizine on the basis of the control group. Comparison were made on treatment effect, pain score before and after treatment, duration time, frequency of attack and occurrence of adverse reactions between the two groups. Results The observation group had obviously higher total treatment effective rate as 96.00% than 76.00% in the control group, and the difference was statistically significant (P<0.05). Before treatment, both groups had no statistically significant difference in pain score, duration time and frequency of attack (P>0.05). After treatment, both groups had lower pain score, shorter duration and less frequency of attack than those before treatment, and their difference was statistically significant (P<0.05). The observation group had lower pain score than the control group, shorter duration time than the control group, and less frequency of attack than the control group. Their difference was statistically significant (P<0.05). Both groups had no statistically significant difference in incidence of adverse reactions (P>0.05). Conclusion Flunarizine combined with nimodipine in the treatment of migraine patients can significantly improve the clinical efficacy, shorten the duration, reduce frequency of attacks with high safety. It is worthy of further promotion in clinical practice.
作者
孟祥君
郅颖
MENG Xiang-jun;ZHI Ying(Department of Internal Medicine-Neurology,Inner Mongolia University of Science and Technology Baotou Medical College First Affiliated Hospita,Baotou 014010,China)
出处
《中国现代药物应用》
2019年第12期92-93,共2页
Chinese Journal of Modern Drug Application
